Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache
- Conditions
- Interventions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2024-03-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 620
- Registration Number
- NCT03971071
- Locations
- 🇦🇺
Holdsworth House Medical Practice, Sydney, New South Wales, Australia
🇺🇸Axiom Research, Colton, California, United States
🇭🇺Borsod-Abauj-Zemplen Megyei Kozponti Korhaz es Egyetemi Oktatokorhaz, Miskolc, Hungary
A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical Therapy
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2022-01-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 152
- Registration Number
- NCT03930186
- Locations
- 🇯🇵
Nippon Life Hospital, Osaka, Japan
🇯🇵Mita Dermatology Clinic, Minato-ku, Japan
🇯🇵Kume Clinic, Sakai-shi, Osaka, Japan
A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
- Conditions
- Interventions
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 31
- Registration Number
- NCT03817424
- Locations
- 🇪🇸
Viela Bio Investigative Site, Sevilla, Spain
A Study to Evaluate the Impact of Apremilast on Magnetic Resonance Imaging (MRI) Outcomes in Adults With Psoriatic Arthritis
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2023-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 123
- Registration Number
- NCT03783026
- Locations
- 🇺🇸
The Doctors of Saint John's Medical Group, Santa Monica, California, United States
🇧🇪UZ Leuven, Leuven, Belgium
🇨🇭Hopital Universitaire Genevois - Beau-Sejour Hospital, Geneve, Switzerland
Safety and Efficacy of Etanercept (Recombinant Human Tumor Necrosis Factor Receptor Fusion Protein [TNFR:Fc]) in Children With Juvenile Rheumatoid Arthritis (JRA)
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-08-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 69
- Registration Number
- NCT03780959
A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of Life
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2022-12-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 277
- Registration Number
- NCT03774875
- Locations
- 🇬🇧
Research Site, Stourbridge, United Kingdom
Expanded Access for CC-10004
- Conditions
- First Posted Date
- 2018-11-14
- Last Posted Date
- 2020-04-29
- Lead Sponsor
- Amgen
- Registration Number
- NCT03740516
- Locations
- 🇺🇸
Celgene, Summit, New Jersey, United States
Open-label Extension of Study 20130173 of Denosumab in Children and Young Adults With Osteogenesis Imperfecta
- Conditions
- Interventions
- First Posted Date
- 2018-08-20
- Last Posted Date
- 2022-12-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 75
- Registration Number
- NCT03638128
- Locations
- 🇬🇧
Birmingham Childrens Hospital, Birmingham, United Kingdom
🇦🇺Perth Childrens Hospital, Nedlands, Western Australia, Australia
🇨🇦Shriners Hospital for Children, Montreal, Quebec, Canada
A Phase1 Study of VIB9600
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT03621605
- Locations
- 🇺🇸
CTI Clinical Trial & Consulting Clinical Research Center, Cincinnati, Ohio, United States
Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-03-14
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Amgen
- Target Recruit Count
- 24
- Registration Number
- NCT03465540
- Locations
- 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇫🇷Institut Gustave Roussy, Villejuif, France
🇺🇸University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, United States